Organisation paid for research Program year 2025 Source: CMS Open Payments

Johns Hopkins Univ

Neither a doctor nor a teaching hospital

Research payments

$33,014,923

406 payments

Through program year 2025, Johns Hopkins Univ is reported as receiving $33,014,923 in research payments, across 406 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$3,235,600	96
2024	Research	$6,048,427	88
2023	Research	$4,070,743	13
2022	Research	$9,070,131	24
2021	Research	$1,671,403	29
2020	Research	$3,100,402	81
2019	Research	$5,818,217	75

Breakdown

Who paid Research payments · program years 2019–2025

ViiV Healthcare Company $11,029,714 12 payments
Amgen Inc. $6,883,612 35 payments
AstraZeneca Pharmaceuticals LP $5,262,098 37 payments
GlaxoSmithKline, LLC. $2,564,121 47 payments
Merck Sharp & Dohme Corporation $2,032,675 8 payments
Siemens Medical Solutions USA, Inc. $1,444,125 101 payments
Genentech, Inc. $1,227,497 4 payments
Alexion Pharmaceuticals, Inc. $601,121 11 payments
AstraZeneca UK Limited $562,079 11 payments
AstraZeneca AB $520,000 2 payments

Studies the money was for Research payments · program years 2019–2025

Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharm $10,290,421 5 payments
Evolocumab in Patients with ST Elevation and non-ST-elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study $1,928,978 3 payments
A Phase II Study of Niraparib With Dostarlimab Therapy As Neoadjuvant $1,855,609 2 payments
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patietns with Germline or Somatic Mutations in DNA Repair Genes $1,766,405 2 payments
Phase I,II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine MK-1439 and Doravirine,Lamivudine,Tenofovir Disoproxil Fumarate MK-1439A in HIV-1-infected Children and Adolescents $1,707,910 4 payments
Evolocumab in Patients with ST Elevation Myocardial Infarction: A Double-blind, Prospective, Randomized Placebo-Controlled Study $1,283,269 2 payments
Next Generation Biomarkers for Progressive Multiple Sclerosis $1,160,039 2 payments
AMG 510 Ph1b Master Protocol 20190135 $1,096,159 3 payments
Evolocumab in Acute Coronary Syndrome (ACS): A double-blind randomized placebo controlled study $1,064,398 4 payments
A Pilot, Phase II study of Olaparib in Patients with Advanced, Metastatic Renal Cell Carcinoma with BAP1 and other DNA-Repair Mutations Cancer. (TRAP trial). $900,917 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.